α-Tocopherol Inhibits Aggregation of Human Platelets by a Protein Kinase C–Dependent Mechanism
- 15 November 1996
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 94 (10) , 2434-2440
- https://doi.org/10.1161/01.cir.94.10.2434
Abstract
Background Epidemiological studies indicate that vitamin E (α-tocopherol) exerts a beneficial effect on cardiovascular disease. The effect of vitamin E has generally been attributed to its antioxidant activity and the antioxidant protection of LDL. Distinct from its effect on LDL, vitamin E is also known to inhibit platelet aggregation and adhesion in vitro, but the mechanism(s) responsible for these observations are not known. Methods and Results Using gel-filtered platelets derived from platelet-rich plasma treated with α-tocopherol (500 μmol/L) or vehicle (0.5% ethanol), we found that inhibition of platelet aggregation by α-tocopherol was closely linked to its incorporation into platelets ( r =−.78; P <.02). Platelet incorporation of α-tocopherol was associated with a significant reduction in platelet sensitivity to aggregation by adenosine 5′-diphosphate, arachidonic acid, and phorbol ester (PMA) by approximately 0.15-, 2-, and 100-fold, respectively. In contrast, platelets treated similarly with butylated hydroxytoluene, another potent lipid-soluble antioxidant, did not demonstrate any change in sensitivity to these agents. Platelet incorporation of α-tocopherol inhibited PMA-induced stimulation of platelet protein kinase C (PKC) as determined by phosphorylation of the 47-kD PKC substrate. In 15 normal subjects, oral supplementation with α-tocopherol (400 to 1200 IU/d) resulted in an increase in platelet α-tocopherol content that correlated with marked inhibition of PMA-mediated platelet aggregation ( r =.67; P <.01). Platelets derived from these subjects after supplementation also demonstrated apparent complete inhibition of PKC stimulation by PMA. Conclusions These data indicate that platelet incorporation of α-tocopherol at levels attained with oral supplementation is associated with inhibition of platelet aggregation through a PKC-dependent mechanism. These observations may represent one potential mechanism for the observed beneficial effect of α-tocopherol in preventing the development of coronary artery disease.Keywords
This publication has 38 references indexed in Scilit:
- Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis.Journal of Clinical Investigation, 1996
- Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation.Journal of Clinical Investigation, 1995
- Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits.Journal of Clinical Investigation, 1994
- Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienolsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1993
- Ultraviolet-treated lipoproteins as a model system for the study of the biological effects of lipid peroxides on cultured cells. III. The protective effect of antioxidants (probucol, catechin, vitamin E) against the cytotoxicity of oxidized LDL occurs in two different waysBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1991
- Beyond CholesterolNew England Journal of Medicine, 1989
- Inhibition of human platelet cyclooxygenase by alpha-tocopherolProstaglandins and Medicine, 1980
- Vitamin E. An inhibitor of the platelet release reaction.Journal of Clinical Investigation, 1976
- Effects of Vitamin E on the Aggregation and the Lipid Peroxidation of Platelets Exposed to Hydrogen PeroxideThe Tohoku Journal of Experimental Medicine, 1974
- Release reaction and energy metabolism in blood platelets with special reference to the burst in oxygen uptakeBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1968